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Abstract 
 The field of specific drug delivery is an expanding research domain. Besides the use of 
liposomes formed from various lipids, natural and synthetic polymers have been developed to 
prepare more efficient drug delivery systems either under macromolecular prodrugs or under 
particulate nanovectors. To ameliorate the biocompatibility of such nanocarriers, degradable 
natural or synthetic polymers have attracted the interest of many researchers. In this context, 
poly(malic acid) (PMLA) extracted from microorganisms or synthesized from malic or 
aspartic acid was used to prepare water-soluble drug carriers or nanoparticles. Within this 
review, both the preparation and the applications of PMLA derivatives are described 
emphasizing the in vitro and in vivo assays. The results obtained by several groups highlight 
the interest of such polyesters in the field of drug delivery. 
 
Introduction 
 Since the term Magic Bullet was coined by Paul Ehrlich nearly a century ago [1], the 
concept of efficient drug delivery systems for therapy in Humans is becoming a reality. 
Indeed, owing to the quest for more effective treatments of several diseases such as cancers, 
numerous researches have been and continue to be performed on the development of systems 
able to deliver high amount of drugs at a specific site of action while decreasing non-specific 
distribution and toxicity. As a consequence of such considerable research works, some of the 
developed nanovectors, especially liposome and nanoparticles, have already received FDA 
approval or are in the preclinical or clinical phases [2-6]. However, even if undeniable 
progresses have been achieved in the design of the ideal drug carriers, several properties, such 
as the biocompatibility, drug loading capacity,  and site-specificity of drug delivery as well as 
a reduced immunogenicity of the carrier following its administration in the body need further 
improvement. 
 Among drug delivery systems designed to address these objectives, polymer based 
carriers have attracted much interest mainly because of the versatile characteristics of 
polymers allowing adjustment of the physico-chemical and biological properties of the 
corresponding nanocarriers. Consequently, several families of polymers have been developed 
to formulate multifunctional drug carriers with properties adjusted to the considered 
application [7]. However, when designing a polymer family, one must keep in mind that the 
resulting materials are prepared to be used in vivo. Therefore, it is necessary to develop 
polymers corresponding to very strict specifications among which the following ones are of 
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great importance: (i). biocompatibility at any stage of the material life and until its complete 
excretion from the body, (ii). the lack of toxicity, (iii). the stealth and reduced 
immunogenicity, (iv). ability to carry large amount of drug(s), (v). the drug delivery at a 
specific site in a sustainable way. 
 Besides these essential properties, the (bio)degradability of the polymers constituting 
the drug delivery systems can be of interest in the sense that the carrier can be eliminated 
from the body as a result of its (bio)degradability. However, this means that the degradation 
process must lead to non-immunogenic, biocompatible and/or (bio)assimilable low molecular 
weight molecules that can be eliminated through bile and/or urine. 
 In the field of drug delivery systems, several stable or (bio)degradable polymers have 
been developed and formulated under either macromolecular linear prodrugs or 
nanoparticulate forms [7-10]. 
As described by Ringsdorf in 1975, a macromolecular linear prodrug, called also 
polymer-drug conjugate, is constituted by a (bio)degradable or biostable polymer backbone 
on which several functionalities are introduced: (i). water or lipid solubilizer as comonomer 
units or blocks, (ii). biologically active molecules linked to the backbone through a 
degradable bound, (iii). targeting agents and body distribution modulator groups [11]. Since 
the Ringsdorf’s model, several systems have been developed [3]. Recently, Pang et al. have 
published a review on the present state and future perspectives of polymer-drug conjugates: 
the most studied polymer-drug conjugates were described in terms of structures and nature of 
the conjugated drug as well as the possible applications and the ongoing clinical trials if any, 
etc. [12]. However, even if such carriers have been widely investigated,  further 
improvements are required to minimize the material’s  heterogeneity by optimizing the 
synthesis, to find versatile linkers for site-specific controlled release and to decrease the 
immunogenicity of the polymer-drug conjugates. 
Besides such linear drug delivery systems, nanoparticulate carriers have emerged 
following the pioneer works realized by Professor Kataoka’s team on macromolecular 
micelles based on amphiphilic block copolymers of  hydrophilic poly(ethylene glycol), PEG, 
and hydrophobic poly(amino acids) blocks [13]. In the meantime, Kabanov’s group developed 
nanoparticulate carriers via the work performed on Pluronic® micelles [14]. 
 In this context, the design of (bio)degradable polymers, whose physico-chemical and 
biological properties can be adjusted either by copolymerization, chemical modifications or 
both, are of great importance [15,16]. Poly(malic acid) (PMLA) (Figure 1) is a very good 
candidate due to the presence of carboxylic acid pendant groups, which can be chemically 
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modified to introduce molecules of interest, and ester cleavable bounds within the polymer 
backbone, allowing the degradation of the polymer main chain into biocompatible metabolites 
[17]. 
 
 
 
 
 
 
 
  
 
Figure 1. Structure of the different forms of poly(malic acid). 
 
Moreover, following the synthesis of a large monomer family of malolactonates 
(MLAR) and their homo- and/or co-polymerization, numerous PMLA derivatives are now 
accessible with physico-chemical and biological properties depending on the nature of the 
repeating units forming the polymer [18-20]. Besides these synthetic macromolecular 
materials, natural poly(malic acid) can be obtained from the plasmodia extracts and from the 
culture medium of Physarum polycephalum [21]. The adjustment of physico-chemical and 
biological properties of the natural PMLA can be realized only by chemical modifications of 
the naturally available polyester. 
 In this article, we present an overview on the researches conducted on both natural and 
synthetic PMLA derivatives for designing multifunctional drug carriers under forms of either 
drug-polymer conjugates or nanoparticles. In a first part, preparation and characterization of 
natural PMLA derivatives will emphasize the in vitro/in vivo assays. The second part will 
focus on both the synthesis of the PMLA’s derivatives and the applications of such synthetic 
polymers as drug carriers. 
 
Drug delivery systems based on natural PMLA 
At the end of the 1980s, Holler et al. have isolated an unusual polyanion from plasmodium 
extracts and from the culture medium of P. polycephalum [21]. They have shown that this 
polyanion inhibits the DNA polymerase α of this organism and that it exhibited a poly(malate) 
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structure [21]. Few years later, we demonstrated that this natural PMLA compound is the β-
ester form of the poly(β-malic acid) obtained by chemical synthesis [22]. The natural 
polyester has attracted the attention of researchers as a result of its potential application in the 
drug delivery system field. The natural PMLA has been indeed used, either unaltered or 
following chemical modifications (Figure 2) to formulate nanoparticles [23-28] or as 
nanoplatforms called Polycefins™ [29-50]. 
 
 
Figure 2. Structures and characteristics of Nat-PMLA derivatives. 
 
Nanoparticles based on natural PMLA  
Muñoz-Guerra et al. have developed derivatives of natural PMLA with the goal of elaborating 
ionic complexes as well as nano- and micro-particles for drug delivery [23-28]. Ionic 
complexes were obtained by mixing aqueous solutions of natural PMLA and 
alkyltrimethylammonium sulfates [23,26]. 
The degradation of such complexes occurred by hydrolysis with a rate that can be 
modulated by changing the chemical structure of either the main chain or the surfactant alkyl 
chain [23,26]. Moreover, up to 30 wt% of the drug erythromycin can be homogenously 
entrapped within the ionic matrix and the kinetics of release followed the hydrolysis profile 
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regardless of the loaded amounts [23,26]. Despites these interesting observations, to the best 
of our knowledge no result of cell based assays have been reported using these biomaterials. 
Besides this work, Muñoz-Guerra et al. have also synthesized derivatives of natural 
PMLA containing hydrophobic groups and prepared the corresponding nano- and micro-
particles [24,25,27,28]. These derivatives have been obtained by reacting diazomethane 
[24,27,28] or by grafting hydrophobic amino acids [25] on natural PMLA. 
Two hydrophobic amino acids have been grafted onto natural PMLA, the L-leucine 
ethyl ester and the L-phenyl alanine methyl ester, in proportions of 30%, 60% and 90% 
without dramatically affecting the molecular weights and polymolecularities of the obtained 
derivatives [25]. Nanoparticles have been prepared from natural PMLA containing 60% of 
amino acid (L-leucine ethyl ester or L-phenyl alanine methyl ester) using the precipitation-
dialysis method. Spherical nanoparticles with a diameter ranging from 70 to 230 nm were 
obtained [25] and cytotoxicity assays realized with two kinds of nanoparticles on various 
cancer cell lines have evidenced a concentration-dependent cytotoxicity but only for polymer 
concentrations above 125 µg/ml. Muñoz-Guerra et al. concluded that such dose-dependent 
cytotoxicity was related to the binding of polymer to cell membranes leading to irreversible 
membrane dys-organization [25]. However, they did not report any experiment evidencing 
such nanoparticles-cell membrane interactions. Finally, they evaluated the use of such 
nanoparticles as drug carriers by studying loading and release with two drugs, Temozolomide 
(TMZ) and Doxorubicin (Dox) [25]. The drug encapsulation was quite low with a fast release 
for TMZ and a slower release for Dox [25]. Unfortunately, no cell cytotoxicity assays and in 
vitro drug delivery of the drug carriers have been conducted. 
Muñoz-Guerra et al. mainly studied the synthesis, characterization and formulation of 
methyl ester of natural PMLA [24,27,28]. Beginning from either 75% or 100% methylated 
natural PMLA, they formulated nano- or micro-particles, by precipitation-dialysis or 
emulsion-evaporation methods with the goal to use these systems as proteins or drugs carriers. 
The micro-sphere diameters were in the range of 1 to 20 µm [28] while the size of 
nanoparticles formulated with the same polymers varied from 100 to 350 nm [24,27]. Several 
proteins [27], an antibiotic molecule [28] and two anti-cancers drugs [24] have been used to 
evaluate the potential of these biodegradable nano- and micro-particles as drug carriers. The 
encapsulation efficiency was shown to be dependent on the nature of the loaded molecule 
while the kinetics of drug release seem to be determined by polymer degradation rate 
[24,27,28]. Finally, cytotoxicity assays using various cancer cell lines have been realized with 
nanoparticles formulated with fully methylated natural PMLA. After one hour of incubation 
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with nanoparticles at a polymer concentration up to 1 mg/ml, the cell viability was not 
affected; however, it decreased significantly after 12 hours of incubation at all the polymer 
concentrations tested. Muñoz-Guerra et al. estimated that such toxicity came from the 
methanol released during polymer degradation [24]. 
  Such research has highlighted the key role of the nature of the ester side groups which 
not only allows the adjustment of physico-chemical properties of the biopolymer but also 
affects its biocompatibility and its interactions with the biological environment.  
 
Nanoplatforms based on natural PMLA 
In the early 2000s, Ljubimova et al. have developed a new type of nanoconjugates based on 
natural PMLA and called Polycefins™ [29-50]. As mentioned above for other nanovectors, 
the natural PMLA has been harvested from the culture broth of P. polycephalum 
microplasmodia [21]. The crude PMLA was purified and characterized with Mw between 50 
and 100 kDa with a polydispersity index of 1.3 before being subjected to a series of chemical 
modifications leading to the synthesis of an all-new set of polymers and the corresponding 
nanoplatforms [41,42]. 
Taking advantage of the carboxylates’ lateral groups, Ljubimova et al. have set up a 
method allowing a highly controlled chemical coupling of various molecules of interest to the 
polymeric PMLA backbone [29-50]. The carboxylate lateral groups were first activated under 
N-hydroxysuccinimidyl esters [41-43,45], then the different molecules of interest, called 
“modules” [43], were chemically coupled to the activated PMLA following a particular 
sequence mainly defined by the molecule sensitivity and the reactive groups [43,45]. 
The first series of chemical coupling consisted in the addition of the more stable 
molecules through amide bonds: 
 - The PEG module (m-PEG5000-NH2) for protecting the nanoplatforms against 
unspecific degradation and scavenging [29-31,33-49]. 
 - Endosome escaping modules which can be activated in response to acidic pH in 
mature endosomes/lysosomes. Different modules have been tested: the valine [35,41], the 
leucine ethylester (LeuEt) [29-31,33,34,36-40,43-48] and the tri-leucine (TriLeu) 
[29,31,33,34,40,45-48]. The evaluation of the membrane lysis by natural PMLA substituted 
by various amino acid derivatives has demonstrated that: (i) natural PMLA derivatives having 
a pH-dependent membrane lysis property, such as natural PMLA substituted by the TriLeu, 
allowed safe and efficient cytoplasmic delivery [32-34,46], and that (ii) natural PMLA 
derivatives with pH-independent membrane lysis properties, such as natural PMLA 
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substituted by the LeuEt, were cytotoxic at high concentrations for several  cell lines. 
Nevertheless, some of these pH-independent natural PMLA derivatives can be used for trans-
membrane drug delivery under certain circumstances [32-34,46]. Moreover with the goal to 
design nanoplatforms with optimal cytoplasmic delivery efficiency and reduced systemic 
toxicity, the mechanisms of membrane permeation for two endosome escaping modules, 
LeuEt and TriLeu have been studied [33]. Natural PMLA bearing TriLeu had a pH-response 
membrane disruption by the “barrel-stave” mechanism (formation of aggregates in solution 
followed by insertion into the membrane forming trans-membranal pores leading to 
membrane permeation) and was less cytotoxic with a more efficient cytoplasmic delivery than 
the nanoplatforms bearing LeuEt, characterized by a “carpet” mechanism (binding to the 
membrane with high affinity leading to membranolysis in a cooperative manner) and a pH-
independent membrane disruption [33]. 
 - A thiol-containing spacer module allowing the chemical coupling of other molecules 
such as targeting agent, drugs or fluorescent dyes [29-31,33-36,38,40-46]. The bioactive 
molecules were then chemically coupled to natural PMLA derivatives through thioether bonds 
for monoclonal antibodies [mAbs] and disulfide bonds for anti-sense oligonucleotides 
(AONs), the disulfide bonds being cleaved by cytoplasmic gluthatione to release free AONs 
[29-31,34-37,39-46]. A fluorescence dye, mainly the Alexa Fluor 680, was also introduced 
before masking the non-reacted thiol groups  for in vitro and in vivo imaging [29-31,34-37,39-
46]. 
Two anti-cancer drugs, the Temozolomide hydrazide (TMZH) [47,48] and the Dox 
[49], have also been chemically bound to natural PMLA nanoplatforms using labile bounds, 
hydrazide bound for TMZH and hydazone linker for Dox. 
From the various natural PMLA based nanoplatforms, Ljubimova et al. performed in 
vitro and in vivo assays in order to evaluate the potential of their nanoplatforms as 
personalized nanomedecine in the field of anti-cancer drug delivery [29-50]. 
In collaboration with Ljubimova’s team, Muñoz-Guerra et al. have prepared and 
characterized nanoplatforms based on partially methylated natural PMLA (25% and 50% of 
methylation) obtained by reaction of diazomethane on natural PMLA [50]. These authors 
have shown that degradation of methylated natural PMLA nanoplatforms was faster in human 
plasma than in phosphate buffered solution (PBS) and faster for low methylated derivatives 
[50]. Several cell based in vitro assays using nanoplatforms based on either 25% or 50% 
methylated natural PMLA have been realized in order to validate their use as biodegradable 
and biocompatible drug delivery systems. They evidenced that only the nanoplatforms 
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constituted by 50% of methylated natural PMLA have a membrane disruption activity, 
property that can be useful to deliver drugs into cells [50]. Besides, in vitro cytotoxicity 
assays conducted on several cancer cell lines have shown that methylated natural PMLA 
exhibited an increasing toxicity with the degree of methylation related to the release of 
methanol occurring during the degradation of the corresponding methylated nanoconjugates 
[50]. In addition, cellular uptake studies realized with Rhodamine-labeled copolymers showed 
a homogenous fluorescence repartition within cells with a higher intensity observed for 
polymers having a higher methylation degree [50].  
 Besides nanoplatforms formulated with methylated natural PMLA, the other systems 
developed by Ljubimova et al. lead to encouraging in vitro and in vivo results. First of all, 
concerning in vitro evaluation of Polycefins™ carrying low molecular weight anti-cancer 
drugs (TMZH and Dox) have been coupled [47-49], the major conclusions are the following: 
 - The half-life of the conjugated TMZH has been significantly increased compared to 
that of  free TMZH and the degradation of the nanoconjugates bearing the TMZH drug was 
faster at 37°C than at 4°C and in human plasma versus  PBS [47,48]. 
 - The release of Dox from the nanoconjugate Nat-PMLA/PEG5000(5%)/GH-Dox(5%) 
was pH-dependent with a fast release at pH5 (about 75% of release after 10 hours of 
incubation) and almost no Dox release at pH7 [49]. 
 - Membrane destabilization studies have evidenced that substitution of around 40% of 
pendant natural PMLA carboxylates of the platform by LeuEt (pH-independent) or TriLeu 
(pH-dependent) lead to good candidates for endosome disruption [47,48]. 
 - Cell viability studies, realized on human glioma cells U87MG (TMZH & Dox), 
T98G (TMHZ) and U251 (Dox) and on invasive breast carcinoma cells, MDA-MB-231 and 
MDA-MB-468 (TMZH & Dox), have evidenced that: (i). the Nat-
PMLA/PEG5000(5%)/GH(5%), the Nat-PMLA/PEG5000(12%)/TriLeu(40%) and the Nat-
PMLA/TriLeu(40%) were well tolerated by all cell lines within the studied concentration [47-
49]; (ii). the Nat-PMLA/PEG5000(12%)/LeuEt(40%) decreased significantly the cell viability 
and was not further considered [47,48]; (iii). the Nat-PMLA/PEG5000(5%)/GH-Dox(5%) 
followed a dose dependent response similar to that of free Dox [49]; in this case, the authors 
suggested adding to the nanoplatform monoclonal antibodies as targeting agent to improve in 
vivo targeted delivery of Dox [49]; (iv). the leads compounds Nat-
PMLA/TriLeu(40%)/TMZH(17%) and Nat-PMLA/PEG5000(2%)/TriLeu(40%)/TMZH(17%) 
on which an anti-human transferrin monoclonal antibody (HuTfR mAb, 0.25%) has been 
grafted showed a significant decrease in the studied tumor cell viability (human glioma and 
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human breast cancer cell lines) [47,48]; in this case also, the authors proposed to move to in 
vivo assays with these two Polycefins™. 
 The major part of the research conducted by Ljubimova’s group is devoted to the 
design of Polycefins™ grafted with PEG5000, anti-sense oligonucleotides [AONs] as anti-
cancer drugs, one or two monoclonal antibodies [mAbs] as targeting agents, L-
valine/LeuEt/TriLeu as membrane disrupting units and, in some cases, a fluorescent dye 
[29,33-37,39,41-46]. They performed several in vitro studies using various human glioma cell 
lines and human breast cancer cell lines, as well as in vivo assays with mice or rats bearing 
either human breast cancer or human glioma cancer. They have shown that the Nat-
PMLA/PEG5000(5%)/AON1(2.5%)/AON2(2.5%)/PEG3400-mAb-OX26(0.23%)/valine(49%) 
entered U87MG cells via a transferrin receptor-mediated endocytosis and that conjugated 
AONs efficiently inhibited target protein expression. After intra-venous injection of 
Polycefin™ labeled with Alexa Fluor 680 dye in nude mice in which human brain cancer 
cells were implanted, the in vivo imaging experiment showed that Polycefin™ accumulated in 
the tumors because of the ability of this polymeric nanoconjugate to cross the Brain-Tumor-
Barrier (BTB) [41]. After its intracranial injection in nude rats bearing human U87MG 
glioblastoma cells, a reduction of the expression of laminin-8 (α4 and β1) chains and of the 
tumor vessel density along with an increase in animal survival have been observed without 
significant effect on other tissues and organ morphology [35]. 
A Polycefin™ bearing a mouse monoclonal anti-human transferrin receptor (TfR) 
antibody was shown to accumulate preferentially in brain and breast tumors after intra-venous 
injection into nude mice and in a lesser extent into kidney and liver leading the authors to 
conclude that Polycefins™ might be of great interest as anti-cancer treatment [44]. 
 To improve direct tumor targeting, they prepared a new Polycefin™ derivative bearing 
PEG chain, AONs, LeuEt and two monoclonal antibodies with different specificities: the 
mouse monoclonal anti-human TfR antibody and the mouse monoclonal tumor-specific anti-
nucleosome antibody 2C5 [36]. The authors demonstrated that this Polycefin™ was 
internalized in U87MG cells in vitro thank to the presence of the 2C5 antibody able to 
recognize the nucleosomes bound to an unknown surface receptor on the glioma cells [36]. 
After its intra-venous injection into nude mice intracranially implanted with human glioma 
cell line U87MG, the highest drug accumulation was observed with Polycefin™ bearing both 
mTfR and 2C5 mAbs: the anti-mouse TfR antibody allowed transporting drug through the 
BTB by binding specifically to the endothelium-expressed TfR and the anti-nucleosome 2C5 
antibody allowed targeting human tumor cells by binding to a tumor cell surface antigen [36]. 
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In their attempt to improve their nanoplatform, Ljibumova et al. have modified the targeting 
agents and the endosome escaping module. For that purpose, they chemically linked to the 
Polycefin™ backbone two monoclonal antibodies, one targeting the BTB (mouse TfR) and 
one targeting tumor cells (human TfR), together with AONs targeting the laminin and the 
development of the angiogenesis within the tumor, and a pH-activated TriLeu as endosome 
escape module [30,31]. Results have shown that: 
 - AONs were efficiently delivered by Nat-PMLA/TriLeu/AON/human TfR into the 
cytoplasm of U87MG and T986 glioma cells and inhibited the synthesis of Laminin-411 α4 
and β1 chains (Western blot analysis). Confocal analysis with double-labeled nanoplatform 
confirmed the entry of the nanoplatform and AONs in the U87MG and T986 glioma cells and 
its escape from the endosome pathway [30,31]. 
 - The Nat-PMLA/TriLeu/AONs/mouse TfrR/human TfR showed the highest 
accumulation 24 hours after its intra-venous injection in human U87MG cells forming brain 
tumors implanted in mice. It should be noted that some of the drug was found in liver and 
kidney. These results suggested that this nanoplatform might be able to pass through the BTB 
and be efficiently internalized into the tumor cells [30,31]. 
 - In these experiments, the tumor growth was significantly decreased after systemic 
injection of the nanoplatform in mice bearing intracranial human glioma U87MG cells,. 
Indeed, the tumor was 90% smaller in nanovector treated mice than in mice treated with PBS. 
Observation of brain sections of nanoplatform-treated mice evidenced mainly tumor remnants 
with significant necrosis and decreased tumoral angiogenesis [Ding, 2009, 2010]. The 
immunostained tumor sections showed a significant decrease in the staining intensity for both 
laminin chains with vessels having sizes almost similar to those in normal brain [30,31]. 
In view of these results, the Polycefin™ nanoplatforms seem to be very promising 
candidates to treat brain diseases. 
 Recently, Ljubimova’s group evaluated the Polycefin™ nanoplatforms for breast 
cancer treatments [29,33,37-39,46]. In a first study, they have prepared a Polycefin™ 
nanoplatform conjugated with: (i) AON directed against HER2/neu mRNA to block new 
HER2/neu receptor synthesis, (ii) anti-HER2/neu antibody trastuzumab [Herceptin] to target 
breast cancer cells and inhibit receptor activity, (iii) transferrin receptor antibody to target the 
tumor vasculature and mediate nanoplatform delivery through the endothelial system, (iv) the 
LeuEt (40%) as endosomal escape module to achieve cytoplasmic delivery of the AON and 
(v) a PEG5000 chain (5%) to improve nanoplatform blood-stream stability [37,38]. They first 
realized in vitro experiments on cells expressing high (BT-474 and SKBR-3) and low (MDA-
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MB-231 and MDA-MB-435) HER2/neu levels. They showed that the Nat-PMLA/HER2/neu 
AON/LeuEt/Herceptin/human TfR/PEG5000 nanoplatform was able to inhibit both the growth 
of all the breast cancer cell lines and the phosphorylation of serine/threonine kinase (Akt). 
Moreover, Ljubimova et al. showed that their Polycefin™ was able to triggered apoptosis in 
both high and low HER2/neu expressing cell lines in vitro [37,38]. Based on these 
encouraging results, they investigated the therapeutic effect of their developed Polycefin™ 
after intra-venous injection in nude mice bearing subcutaneous human breast tumor 
xenografts (BT-474 cell lines). The treatments were well tolerated by mice upon 
administration of the Polycefin™. The treatment induced tumor growth inhibition with a 
synergic effect of the presence of HER2/neu AON and Herceptin, and appearance of necrotic 
areas with little tumor tissue remaining [37,38]. Western-blot analysis of tumors after 
treatments showed that  Polycefin™ induced strong and sustained inhibition of HER2/neu 
tumor expression and phosphorylation of Akt, as well as the induction of apoptosis [37,38]. 
These results constitute a proof of concept for the use of natural PMLA nanoplatforms for 
cancer therapy. 
 With the aim to improve the treatment of HER2/neu positive breast cancer, Ljubimova 
and coworkers have slightly modified the nanoplatform described above. Because Interleukin-
2 (IL-2) can be considered as a potential cancer treatment with, however, a low therapeutic 
efficacy due to its rapid blood clearance and severe side effects [51], they designed a natural 
PMLA nanoplatform bearing, among other modules, a modified human IL-2, which was 
obtained by its fusion to the C-terminus of the  heavy chains of an anti-HER2/neu IgG3, anti-
HER2/neu IgG3-(IL-2) [29,34]. This Polycefin™, called PMLA-fusion nanobioconjugate, 
containing 5% of mPEG5000 chains, 40% of LeuEt, 0.25% of anti-human-HER2/neu IgG3-
(IL-2) to target the tumor and function as immunomodulator while 2.5% of AONs trigger the 
inhibition of both human and mouse Laminin expression (α4 and β1 chains) [34]. After 
showing that IgG3-(IL-2) conjugated to natural PMLA retained the HER2/neu targeting 
properties of the anti-body and that the biological activity of the IL-2 within the complex anti-
HER2/neu IgG3-(IL-2) was maintained, Ljubimova et al. evaluated, by confocal microscopy, 
cellular uptake of the PMLA-fusion nanobioconjugate by BT-474 human breast cancer cells 
expressing high level of HER2/neu. Their results suggested that the presence of anti-
HER2/neu IgG3-(IL-2) on the nanoplatform allowed both the cell surface binding and the 
cellular uptake of the nanobioconjugate [29,34]. In vivo biodistribution studies were realized 
on athymic mice subcutaneously injected with BT-474 human breast cancer cells and after 
intra-venous injection of PMLA-fusion nanobioconjugate without AONs. The 
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nanobioconjugate preferentially accumulated at the tumor site and in a lesser extent in the 
liver [29,34]. Anti-cancer activity and immunoactivation by the PMLA-fusion 
nanobioconjugate were also evaluated after intra-venous injection in a syngeneic model of 
immunocompetent BALB/c mice implanted with D2F2/E2 cancer cells [29,34]. Results 
evidenced that only treatment with the PMLA-fusion nanobioconjugate increased the survival 
of treated mice and the serum level of anti-HER2/neu IgG1 and IgG2a. Such results suggested 
an enhanced of the humoral and cellular immune responses [29,34]. 
 Furthermore, Ljubimova et al. adapted their Polycefin™ nanoplatform to the treatment 
of triple-negative breast cancer (TNBC) [39,46]. In a first study, they chemically bound to 
natural PMLA nanoplatform 5% of m-PEG5000, 40% of LeuEt, 2% of epidermal growth factor 
receptor (EGFR) AON to inhibit the synthesis of EGFR, protein highly expressed in TNBC, 
0.12% of anti-tumor nucleosome-specific monoclonal antibody mAb [2C5] to target breast 
cancer cells and 0.12% of anti-mouse transferrin receptor (TfR) antibody for delivery through 
the endothelium of blood vessels [39]. Western-blot analysis performed on EGFR expressing 
cells (MDA-MB-468) and cells expressing low EGFR levels (SKBR-3) demonstrated that 
Polycefin™ derivative efficiently inhibited EGFR expression in both cell lines. To confirm 
the tumor targeting property of mAb 2C5, a variant of Polycefin™ containing mAb 2C5 and 
EGFR-AON was injected intra-venously into athymic mice bearing MDA-MB-468 human 
breast cancer cells. The biodistribution study showed that this nanobioconjugate accumulated 
mainly in tumor with a non negligible accumulation in kidney and liver. The introduction of 
the second antibody, the TfR, on the Polycefin™ nanoplatform allowed to a more important 
drug accumulation into implanted tumor an a reduced accumulation into kidney and liver 
[39]. 
Finally, the Nat-PMLA/PEG5000/EGFR-AON/mAb 2C5/TfR/LeuEt was intra-venously 
injected into MAD-MB-468 tumor-bearing mice: this Polycefin™ induced the most 
pronounced anti-cancer effect with a strong tumor growth inhibition, a significant necrotic 
effect in treated tumor, a high inhibition of EGFR expression and of phospho-Akt levels in 
tumor [39]. In view of their results, the authors concluded that this new generation of 
nanobioconjugate might represent a powerful way to treat TNBC. 
Before engaging Polycefins™ into clinical trials, Ljubimova and colleagues have 
performed a detailed evaluation of the toxicity and immunogenicity in vitro and in vivo of the 
Polycefin™ designed for TNBC treatment [46]. For this study, they have prepared a 
Polycefin™ bearing AONs targeting EGFR, Laminin α4 and/or Laminin β1 protein synthesis, 
LeuEt modules, mPEG5000, MsTfR mAb targeting mouse endothelial cells in tumor vessels 
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and HuTfR mAb for binding to human tumor cells and nanodrug internalization. The 
investigators have shown that chronic exposure of nude mice to nanobioconjugates of natural 
PMLA at both low and high doses did not induce toxic changes in blood cell count or 
metabolic effects. PMLA nanoplatforms were well tolerated in vitro and in vivo in extreme 
dosage without toxicity and immune reactions. It is important to note that only low 
complement activation has been observed at very high dosage of the nanobioconjugate 
(1mg/kg) [46]. In addition, Polycefin™ nanoplatforms inhibited the growth of EGFR-positive 
triple negative breast tumor cells in nude mice after intra-venous multiple injections. For both 
treatments, the Nat-PMLA/AONEGFR,α4,β1/MsTfr/HuTfR nanoconjugate showed a significant 
tumor growth inhibition. These results lead the authors to conclude that this dual-action 
nanodrug significantly inhibited the TNBC growth and angiogenesis [46]. From the data, 
Polycefin™ derivatives might be considered as versatile nanoplatforms for treatment of 
various cancers, such as breast and brain cancers, because of the possibilities to chemically 
couple several molecules of interest and the low toxicity and immunogenicity of the native 
natural PMLA backbone. 
 
Drug delivery systems based on synthetic poly(malic acid) 
Besides the use of natural PMLA derivatives for the design of drug delivery systems, 
synthetic poly(β-malic acid) has been the first polymer synthesized to be formulated as water-
soluble drug carrier [52]. The chemical synthesis of PMLA has been conducted from two 
natural molecules, the malic acid [53] or the aspartic acid [54,55], and by different 
polymerization techniques, ring opening polymerization [54-56], polycondensation [57] or 
enzymatic polymerization using lipases [58]. The synthetic PMLA (Figure 1) is found under 
the β-form (ring opening and enzymatic polymerizations), the α-form (ring opening 
polymerization) or a mixture of both α- and β-forms (polycondensation). These PMLAs have 
been successfully used to formulate of various drug delivery systems by several research 
teams. 
First, applications of synthetic PMLA derivatives as macromolecular prodrugs are 
developed and summarized in Figure 3. 
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Figure 3. Structures and characteristics of water soluble synthetic PMLA derivatives. 
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residues have been also chemically coupled on poly(α-malic acid)-5FU in order to evaluate 
the cell specific targeting of the resulting conjugate [60]. Ouchi et al. have first studied the 
degradation of their macromolecular conjugates in vitro in order to determine the release of 
5FU from poly(α-malic acid)-5FU conjugates [59-61]. They evidenced that the hydrolysis 
rates of the main-chain ester bonds of the poly(α-malic acid)were much slower than those of 
lateral ester, amide and carbamoyl bonds leading to a slow release of 5FU [59-61]. The anti-
tumor activity of poly(α-malic acid)-5FU conjugates has been evaluated after intra-peritoneal 
injections into female CDF1 mice bearing P388 lymphocytic leukemia cells [59,61]. The 
poly(α-malic acid)-5FU conjugates lead to an improved survival rate with no acute toxicity at 
a dose of 200-800 mg/kg [59,61]. The conjugates bearing saccharide residues as targeting 
agent also seemed to have significant anti-tumor activities with no acute toxicity in the 
studied dose ranges after intra-peritoneal injection in the same animal model [60]. Ouchi et al. 
concluded that the 5FU side effects were significantly decreased by its attachment to poly(α-
malic acid) backbone bearing or not saccharide residues as targeting agent [59-61]. 
Interestingly, the nature of the saccharide affected the in vitro growth inhibition in SK-
Hep-1 and HLE human hepatoma cells and HeLa uterocervical carcinoma cells [60]. The 
poly(α-malic acid)-5FU-galactosamine conjugate had the highest growth inhibitory effect on 
SK-Hep-1 and HLE cells while no effect has been observed on HeLa cells. Blocking the 
galactose receptors of human hepatoma cells with the trimer of galactosamino-saccharide 
induced a decrease in the growth inhibitory effect of poly(α-malic acid)-5FU-galactosamine 
conjugates demonstrating that the galactosamide allowed targeting of 5FU to hepatoma cells 
via galactose-receptor [60]. 
 The same group has also prepared a poly(α-malic acid) derivate on which the Dox 
molecule was linked through ester or amide bounds [62]. As expected, the release rate of Dox 
conjugate to poly(α-malic acid) through ester bounds was faster than compared to that of Dox 
conjugated to poly(α-malic acid) through amide bounds [62]. Cytotoxicity assays have been 
realized in vitro using P388 D1 lymphocytic leukemia cells. While the Dox linked to poly(α-
malic acid) through ester bond induced a cytotoxicity similar to free Dox, the Dox bound to 
poly(α-malic acid)through amide bound had a lower cytotoxicity [62]. Such results have led 
Ouchi’s group to conjugate onto their poly(α-malic acid)-amide-Dox various saccharide units 
as targeting agents and to study both the Dox release and the in vitro cytotoxicity of these 
conjugates on cancer cell lines [63,64]. As previously observed, free Dox was released faster 
from the poly(α-malic acid) conjugates when Dox was linked through ester bonds and under 
acidic conditions compared to the poly(α-malic acid)-amide-Dox [63]. The cytotoxicities of 
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Dox linked to poly(α-malic acid) were lower than with the free Dox [64]. The introduction of 
saccharide units seemed to have no influence on cytotoxicities of the corresponding Dox-
conjugates on AZ521, KNS and Hela cells. In contrast, the presence of galactosamine as 
saccharide units on the poly(α-malic acid)-amide or ester-Dox had led to higher cytotoxicities 
on HLE and HepG2 hepatoma cells than those observed for non-glycosylated poly(α-malic 
acid)-amide or ester-Dox and for free Dox [63,64]. The authors concluded that such higher 
activity resulted from galactose receptor-mediated uptake of the conjugate into hepatoma cells 
but further studies are still needed to confirm the interest of such poly(α-malic acid)-Dox-
galactosamine conjugates. 
 In a different context, copolyesters containing malic acid and propane 1,2-diol units 
have been also prepared with the goal to use them as enteric coating materials for tablets 
containing sodium diclofenac [65-67]. Bakr et al. have shown that the physico-chemical 
properties of the copolyesters remained unchanged in simulated gastric fluid (pH1.2) but these 
polymers gradually degraded in simulated intestinal fluid (pH7.4). These authors have 
evidenced that 80% of the sodium diclofenac were released within 45 min at pH7.4 and 
concluded that the release patterns of malic acid copolyesters coated tablets might correspond 
to the British Pharmacopea drug release profile of enteric coated tablets [65-67]. Despites 
such results and to the best of our knowledge, no additional data have been published for 
these applications. 
 In 2005, Chan-Park et al. have synthesized and characterized a 2-hydroxylethyl 
methacrylate (HEMA) grafted on poly(ε-caprolactone-co-RS-β-malic acid) with the goal to 
prepare functionalized and photopatternable biodegradable polyester for applications in  
micropatterned tissue engineering scaffolds [68]. These authors have concluded that their 
liquid copolymer possessed the required properties for UV microembossing, a liquid 
micromodeling technique, [68]. However, to date neither in vitro nor in vivo assays have been 
reported. 
 In the domain of the preparation of biocompatible materials based on PMLA 
derivatives, some research works have been realized on the synthesis and characterization of 
PMLA-based hydrogel [69-71]. He et al. prepared a poly(α,β-malic acid) by polycondensation 
of malic acid, on which they grafted HEMA molecules using classical coupling reactions. The 
resulting poly(α,β-malic acid)-graft-HEMA was then UV-crosslinked in presence of Irgacure 
2959 as photoinitiator in water thus leading to the expected hydrogel [69]. These authors 
realized only physico-chemical characterization of the obtained hydrogel: water uptake, which 
varied in function of the HEMA content, and degradation behavior. They found that 
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degradation was related to HEMA content and occurred simultaneously at the surface and in 
the bulk [69]. He and colleagues al. further modified poly(α,β-malic acid)-based hydrogel 
prepared a supramolecular injectable hydrogel by mixing methylated-poly(ethylene glycol)-
graft-poly(α,β-malic acid) [mPEG-g-poly(α,β-malic acid)], obtained by coupling mPEG on 
poly(α,β-malic acid) [70]. The polyrotaxanes obtained by mixing mPEG-poly(α,β-malic acid) 
and α-cyclodextrin (α-CD) in water were shown to act as physical cross-linked hydrogel with 
properties (gelation condition, hydrogel morphology, etc.) depending on their composition  
especially the content of copolymer and α-CD and the molecular weight of mPEG. Dox-HCl 
has been encapsulated within the network with amounts varying between 0.015 and 0.034 
wt% depending on the network composition. The Dox-HCl release in PBS at 37°C was quite 
fast within the first hours of incubation and was shown to be dependent on the hydrogel 
composition [70]. Finally, the anti-tumor effect of the released Dox-HCl was evaluated in 
vitro on U87MG glioma cancer cells. The variation of cell morphologies and the growth 
inhibition of cancer cells led the authors to conclude that their injectable hydrogel might be a 
new drug delivery system injectable in the vicinity of the tumor with minimal invasiveness 
[70]. 
Finally, Chan-Park and coworkers have prepared and characterized biodegradable 
hydrogel based on PMLA derivatives as drug delivery systems [71]. A block copolymer 
PMLA-b-PEG-b-PMLA was synthesized by polymerization of benzyl malolactonate in 
presence of PEG and modified by addition of methacrylate groups on both chain ends 
(PEGMLAAc). These authors mixed methacrylated O-carboxychitosan (OCMCS), 
PEGMLAAc and PEG diacrylate (PEGDAc) in various proportions in water. These solutions 
were able to form hydrogels after photopolymerization of acrylate groups [71]. On the PMLA 
block of the hydrogel, the carboxylic acid lateral groups were used to chemically link the Arg-
Gly-Asp (RGD) peptide. The RGD-grafted hydrogels were used as coating matrix for smooth 
muscle cell (SMCs) that have grown over time with no apparent toxicity. These hydrogels 
were shown to be degradable with a moderated release of malic acid at physiological pH. 
Therefore, such PMLA-based hydrogels might be considered as promising coating substrate 
for long-term cell culture and proliferation [71]. 
 In the design of biodegradable materials for tissue engineering, poly(lactide-co-malic 
acid) copolymers were synthesized by ring-anionic polymerization of lactide (L or DL 
emantiomer) and RS-benzyl malolactonate [72-78]. The authors studied the properties of such 
biodegradable polymers in terms of degradation rates, thermal properties and morphology of 
the block copolymers. All these parameters varied upon the copolymer composition and the 
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synthesis temperature [72,73]. The various synthesized copolymers were then evaluated for 
cell colonization and biocompatibility as well as for tissue engineering [74-78]. He and 
coworkers have tested the cell adhesion on films prepared from poly(L-lactide-co-β-malic 
acid) using 3T3 mice fibroblasts. Their study evidenced that these fibroblasts could grew well 
on both the surface and inside the scaffolds [74]. 
With the aim of designing biocompatible matrices that would support cell culture, the 
authors have also evaluated the potential of the amorphous biodegradable poly(L-lactide-co-β-
malic acid) grafted or not with bioactive RGD peptide to allow the culture of primary 
umbilical artery smooth muscle cells [75]. The cell viability was improved and their 
proliferation and spreading were shown to be better on films made by poly(L-lactide-co-β-
malic acid) with or without RGD peptide than on films prepared from PLA [75]. Poly(L-
lactide-co-β-malic acid) polymers also support the culture of SMCs leading the authors to 
conclude that their functionalized copolymers might be of interest for vascular tissue 
engineering [76]. 
Few years later, another research team evaluated the uses of films based on poly(L-
lactide-co-β-malic acid) on which they grafted hydroxyl or extended carboxyl arms [78] or 
Gly-Arg-Gly-Asp-Ser (GRGDS) peptide [77] for vascular tissue engineering. In the search of 
an ideal biocompatible material for vessel engineering, Wang et al. synthesized a PMLA-
based copolymer with extended carboxyl arms to enhance cell adhesion of endothelial cells 
and improve hemocompatibility [78]. They compared the properties of this new copolymer to 
the PMLA-based copolymers with hydroxyl arms and PLA in terms of degradation rates, 
water uptakes, surface morphologies, platelet adhesion, hemacompatibilities and Human 
umbilical vein endothelial cells (HUVECs) attachment and proliferation [78]. 
The results of their studies showed that the degradation rates of poly(lactide-co-β-
malic acid) with pendant hydroxyl arms (PMLA-HE) and poly(lactide-co-β-malic acid) with 
extended carboxyl arms (PMLA-ECA) were similar with slow degradation rates during the 
first month accelerating thereafter. The intrinsic and extrinsic coagulation times representing 
the hemocompatibility were not influenced by the presence of both copolymers. The PMLA-
ECA reduced, however, significantly the adhesion of blood platelets without activating them 
while allowing the best HUVECs attachment and proliferation [78]. 
Finally, Wang and colleagues evaluated the blood compatibility of poly(L-lactide-co-
β-malic acid) on which a GRGDS peptide has been grafted [77]. This copolymer, containing 
9% of malic acid units and 2.9 mol% of carboxyl residues linked to GRGDS peptide, was 
shown to: (i) possess a quite high hydrophilicity; (ii) activate neither the intrinsic nor the 
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extrinsic coagulation pathway; (iii) significantly decrease the adhesion and activation of blood 
platelets; (iv) promote the adhesion and proliferation of HUVECs [77]. Coagulation assays 
and platelet adhesion were also studied on the HUVECs plated on the copolymers: no 
difference was observed before and after cell seeding. From their results, the authors 
concluded that the cells cultured on their films showed a good anti-thrombogenicity and that 
these biodegradable films might be of interest for vascular tissue engineering [77]. 
 All these results have highlighted that it is possible to modulate physico-chemical 
properties (degradation rate, hydrophilicity, biocompatibility, etc.) of PMLA derivatives by 
either grafting adapted lateral groups or by copolymerization with other monomers such as 
LA. 
 Besides the design of macromolecular water soluble prodrugs, hydrogels and films, 
numerous studies have been conducted on the elaboration of biodegradable nanoparticulate 
systems for site-specific delivery of drugs (Figure 4). 
In this field, Stolnik et al. published the first results on the preparation and 
characterization of biodegradable colloidal particles prepared from amphiphilic PMLA 
derivatives [79-81]. Different poly(β-malic acid-co-benzyl malate) copolymers were 
synthesized by anionic ROP of benzyl malolactonate followed by partial catalytic 
hydrogenolysis. These authors performed only physico-chemical characterization of the 
corresponding particulate systems and showed that their size, surface charge and surface 
chemistry varied considerably with the copolymer composition: the presence of malic acid 
units resulted in the formation of larger nanoparticles with a significant decrease in zeta 
potential [79,80]. The degradation rates of such nanospheres were slow and most likely varied 
with copolymer composition: the presence of benzyl ester functions reduced the hydrolysis 
rate of ester bonds in the polymer main chains [81]. Even though such systems seemed to be 
of interest as drug delivery systems, no in vitro and in vivo assays have yet been published. 
Over a decade ago, Osanai and colleagues have studied the effects of the complexation 
between liposomes and PMLA on aggregation and encapsulation behavior with the goal to 
prepare pH-sensitive liposomes [82]. The authors prepared a poly(sodium-β-DL-malate-co-
octyl-β-DL-malate) by copolymerization of benzyl malolactonate and octyl malolactonate 
followed by catalytic hydrogenolysis. This copolymer was then mixed with the soy lecithin 
L,α-dipalmitoyl phosphatidylcholine (DPPC) to formulate liposomes with a polymer corona 
[82]. The obtained liposomes were shown to have a spherical structure with diameters in the 
range of 30 to 55 nm, the octyl groups introduced on the PMLA working as anchors 
stabilizing therefore the complexation between lipid and PMLA [82]. Osanai et al. studied the 
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influence of the pH on aggregation and fusion of liposomes as well as on the calcein release 
from the liposomes. Through their study, they showed that the aggregation and fusion were 
low at neutral pH and increased under acidic pH conditions. The same behavior was observed 
for calcein release, low at neutral pH and faster under acidic conditions [82]. These 
nanovectors have unfortunately not been further characterized despite these interesting 
features.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structures and characteristics of synthetic PMLA derivatives under nano-object 
forms. 
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Several studies also report studies realized with poly(lactide-co-β-malic acid)  
derivatives for the design of degradable nanoparticles [83-85]. Wang et al. have synthesized 
an amphiphilic di-block copolymer, the MePEG-b-poly(lactide-co-β-malic acid)  by 
hydrogenolysis of the MePEG-b- poly(lactide-co-β-benzyl malate)  obtained by ring-opening 
copolymerization of DL-lactide and RS-benzyl malolactonate using MePEG as the initiator 
and stannous octoate as the catalyst [84]. The corresponding nanospheres were prepared by 
the solvent evaporation method The images obtained by TEM showed that the nanospheres 
prepared from the protected block copolymers had a compact spherical morphology while 
those prepared from the deprotected block copolymers had an incompact spherical 
morphology. Moreover, the in vitro experiments evidenced that the degradation rates 
increased with the amounts of hydrophilic malic acid units [84]. Unfortunately, no in vitro or 
in vivo assays have been realized so far on such nanospheres. 
Recently, Nottelet et al. have prepared and characterized micelles based on the fully 
degradable block copolymers, the PMLA-b-poly(dihexyllactide), the PMLA-b-
poly(monohexyllactide) and the PMLA-b-PLA. The first step consisted in the ring opening 
polymerization of benzyl malolactonate generating the PMLABe block which was used in the 
2nd step for the ring opening polymerization of dihexyllactide (DiHeLA), monohexyllactide 
(MoHeLA) or LA. The last step, catalytic hydrogenolysis of the PMLABe blocks, led to the 
expected amphiphilic block copolymers [83]. 
The corresponding micelles were prepared by adding an acetone solution of block 
copolymers into water or PBS at physiological pH under sonication. The resulting micelles 
varied in size with diameter ranging from 21 to 60 nm and their critical micellar concentration 
[cmc] between 7 and 100 mg/L [83]. Stability and loading capacity of these micelles 
evaluated with Nile Red fluorescence probe evidenced that the PMLA-b-PDiHeLA polymeric 
micelles presented: (i) an acceptable stability at room temperature, (ii) a reasonable stability 
during the first two weeks at pH7.4 and 37°C followed by a quite fast degradation, and (iii) a 
faster degradation at pH5 and 37°C. The authors concluded that the properties of PMLA-b-
PDiHeLA polymeric micelles might be of interest for controlled drug release in vivo [83]. 
The last study we wish to present here was conducted by Wang and coworkers in 2010 
on biodegradable magnetic fluorescent magnetite/poly(lactide-co-α,β-malic acid)  composite 
nanoparticles for stem cell labeling [85]. The block copolymers were synthesized by two 
successive polycondensations: the DL-lactic acid was first polycondensated to give PLA on 
which DL-malic acid was polycondensated compound leading to the expected block 
copolymers. FITC was then grafted on some of the carboxylic acid lateral groups of the 
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poly(α,β-malic acid) block. Magnetite nanoparticles were then modified with the prepared 
fluorescent block copolymer and the resulting FITC-poly(lactide-co-α,β-malic acid)-MNPs 
nanoparticles were subjected to several tests. First the magnetic properties of these 
nanoparticles have been evaluated and the results showed that they were suitable as magnetic 
resonance imaging T2-contrast agent. Moreover, these particles were shown to be non toxic 
towards RAW macrophages, 3T3 fibroblasts and human mesenchymal stem cells (hMSCs). In 
addition, FITC-poly(lactide-co-α,β-malic acid)-MNPs were shown to be rapidly internalized 
into hMSCs and they had adverse effect on the osteogenic and adipogenic differentiation 
potentials of hMSCs. Finally, such interesting results led the authors to conclude that the 
magnetite nanoparticles they developed might be excellent magnetic fluorescent tracking 
agents for stem cells [85]. It is important to note that the use of PMLA, obtained by enzymatic 
polymerization using lipases, for surface coating of magnetic nanoparticles with applications 
as medical resonance imaging was patented [86]. 
 With the goal to administrate new specific siRNAs able to target estrogen receptor 
alpha (Erα) without affecting ERβ, Bouclier et al. studied the possibilities to load these 
siRNAs into nanocapsules constituted by PEG-b-poly(ε-caprolactone-co-dodecyle malate) 
block copolymers [87]. In this report, the authors described the synthesis and the 
physicochemical characterization of siRNA loaded nanocapsules as well as results of several 
in vitro and in vivo assays. The PEG-b-poly(ε-caprolactone-co-dodecyle malate)  based 
nanocapsules, prepared by double emulsion technique in presence or in absence of siRNAs, 
had a diameter of 105 to 118 nm across with a slightly negative zeta potential and a siRNA 
charge yield of 72% [87]. The PEG-b-poly(ε-caprolactone-co-dodecyle malate)  based 
nanocapsules were not toxic towards MCF7 cells in vitro. The authors investigated the time 
course of siRNA release from the nanocapsules and showed that the presence of proteins 
increased siRNAs release rate, and that a burst effect was observed followed by a period of 
slower release, phenomenon explained by the nanocapsules morphology [87]. Before moving 
to in vivo assays, the authors showed that siRNA loaded into PEG-b-poly(ε-caprolactone-co-
dodecyle malate) nanocapsules significantly decreased the expression of Erα into MCF7 cells 
in vitro proving the efficient uptake of siRNA into cells [87]. Finally, siRNA loaded PEG-b-
poly(ε-caprolactone-co-dodecyle malate)  nanocapsules was intravenously injected into nude 
mice bearing estrogen-dependent brain cancer cell xenografts. Under the experimental 
conditions, the authors observed a significant decrease in Erα expression in tumors and a 
slight decrease in tumor growth [87]. The authors concluded that the formulations need to be 
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optimized to lead to more significant effects on tumor regression but these nanocapsules, 
however, present a real potential as nucleic acids and drug carriers. 
 To prepare site-specific macromolecular micelles, Yang and colleagues  utilized 
similar block copolymers of PEG-b-poly(ε-caprolactone-co-malic acid), on which they 
introduced folic acid (FA) at the free chain end of the PEG block as targeting agent and Dox 
on lateral carboxylic acid lateral functions of the malic acid units through the pH sensitive 
hydrazone linker [88]. The obtained micelles had a diameter of about 25 nm with 14% of 
encapsulated Dox. At pH7.4, almost no Dox was released while the Dox release was 
increased at lower pH values. The FA-conjugated micelles were shown to be effectively 
uptaken by 4T1 cells in vitro leading to the induction of cytotoxicity through the release of 
Dox [88]. 
 Other interesting studies concern the design of either nanoparticles prepared from 
chitosan modified by linoleic acid and poly(β-malic acid) [89,90] or polyelectrolyte complex 
(PEC) nanoparticles obtained by mixing poly(lactide-co-α,β-malic acid)) with chitosan [91]. 
Yin et al. double grafted on chitosan the hydrophobic linoleic acid and a hydrophilic poly(β-
malic acid) having at one chain end lactic acid obtained by ring opening polymerization of 
benzyl malolactonate in presence of lactic acid [89,90]. In a first study, Yin et al. prepared 
nanoparticles by a sonication method, from the synthesized chitosan derivative. The obtained 
nanoparticles had diameters in the range of 190-330 nm with negative zeta potential (around -
10 mV) while the critical aggregation concentration (CAC) was found to be dependent on the 
hydrophilic/hydrophobic ratio controlled by the number of linoleic acid and PMLA molecules 
grafted on the chitosan [89]. Paclitaxel (PTX) has been encapsulated into nanoparticles during 
the preparation step by sonication with loading efficiencies of around 70 w%. The PTX 
release profile from all the prepared nanoparticles in vitro (PBS pH7.4 containing 0.1% of 
tween 80) showed a very fast PTX release within the first hour (burst effect) followed by a 
slightly slower PTX release. Almost 80% of encapsulated PTX were released after 12 hours 
of incubation. The in vitro hemolytic effects of the nanoparticles, representative of blood 
compatibility in vivo, were quite low, indicating that the prepared formulations might be 
suitable for intravenous injections and hematological applications [89]. Minimal acute toxicity 
has been observed for one of the formulations. Indeed, when this formulation was injected 
intravenously in mice at a dose of 625 mg/kg, no sign of toxicity and death of animals have 
been observed. Moreover, a higher dose (1250 mg/kg) induced only moderate and transient 
signs of toxicity, which disappeared after 24 hours [89]. Eight days after the intravenous 
injection of this formulation loaded with PTX, tumor volume and weight were significantly 
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decreased, meaning that PTX encapsulated into the chitosan based formulations was more 
effective than PTX alone [89]. 
In addition, Yin and colleagues have also prepared and characterized chitosan based 
formulation showing a positive surface charge for the encapsulation of DNA with the goal to 
develop degradable gene delivery systems. As described above, they synthesized amphiphilic 
linoleic acid and PMLA double grafted chitosan with substitution degree lower than those of 
the previous study [89] allowing them to obtain, by sonication of a buffered solution at pH5.5 
containing the copolymer, nanoparticles with diameters varying from 170 to 260 nm and zeta 
potential between +30 to +50 mV [90]. They prepared the nanocomplexes by mixing these 
nanoparticles with the plasmid pEGFP encoding the Green Fluorescent Protein (GFP). Stable 
and uniform nanoparticle/pEGFP nanocomplexes were obtained at pH5.5 with diameter lower 
than 300 nm. These researchers demonstrated that hydrophobic linoleic acid and hydrophilic 
PMLA substitutions allowed the suppression of non-specific adsorption, the reduction of 
interactions within the nanoparticle/pEGFP nanocomplexes and enhanced DNA release. On 
the other hand, they demonstrated that cell adsorption and uptake of the nanocomplexes were 
promoted by higher content of linoleic acid and lower PMLA substitution degree [90]. In vitro 
transfection assays on HEK 293 cells demonstrated that the nanocomplexes with a weight 
ratio of 12 had a high gene expression level with 34 % of GFP positive HEK cells detected. 
This nanocomplexe has been selected for intramuscular transfection assay. It exhibited in vivo 
transfection capability superior to that observed for chitosan/pEGFP and 
poly(ethylenimine)/pEGFP nanocomplexes indicating that PMLA substituted chitosan might 
be of interest in the drug and gene delivery field [90]. 
 In 2014, Wang and coworkers developed a PEC based on interactions between 
chitosan and the poly(lactide-co-α,β-malic acid) which was obtained by polycondensation of 
L-malic acid and DL-lactic acid [91]. The authors observed that: (i) stable spherical 
nanoparticles were formed when the pH of the solution was in the range of 3 to 6, (ii) their 
diameters were influenced by the composition of chitosan and the copolymers and were in the 
range of 300 to 600 nm, (iii) the prepared PEC micelles had a negative surface charge of 
about -30 mV, and (iv) their CAC varied from 0.009 to 0.105 mg/ml [91]. As a drug model, 
Dox was loaded into these PEC micelles and slightly increased the micelle diameter [91]. The 
drug release at different pH evidenced an initial burst effect within the first hours followed by 
a slower release regardless of the pH value [91]. In vitro cytotoxicity assays realized with the 
PEC nanoparticles on L929 cells showed that such nanovectors were not cytotoxic [91]. 
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Despite inconsistent results, the authors concluded that their PEC micelles might be of interest 
as pH sensitive drug delivery systems [91]. 
 An interesting study was realized by Dove et al. who prepared nanoparticles from 
stereocomplexation between PEG-b-poly(L-β-benzyl malate) and PEG-b- poly(D-β-benzyl 
malate) which were synthesized by ring opening polymerization of R- or S-benzyl MLAR 
using PEG as macroinitiator and 4-methoxypyridine as catalyst [92]. These authors realized 
only partial physicochemical characterizations of their micelles showing that micelles formed 
by the stereocomplexation of both block copolyesters were more stable than the ones prepared 
from either PEG-b-poly(L-β-benzyl malate) or PEG-b-poly(D-β-benzyl malate) and might find 
applications as degradable polymeric micelles for drug delivery [92].  
 In 2011, Shen and colleagues have prepared and characterized biocompatible and 
biodegradable nanocapsules obtained by surface polycondensation of malic acid on silica 
nanoparticles as sacrificial templates [93]. The obtained poly(α,β-malic acid)grafted silica 
nanoparticles was cross-linked and the silica nanoparticles templates were eliminated leading 
to hollow polymeric nanocapsules [93]. Despite the lack of in vitro and/or in vivo assays, this 
kind of nanocapsules as well as their preparation strategy might be useful for the development 
of biocompatible nanovectors based on poly(malic acid) derivatives. 
 Recently, investigators utilized randomly hydrophobized poly(dimethylmalic acid) to 
solubilize water-insoluble drugs as Amphotenicin B (AmB) and clofazimine [94]. These 
authors first showed that the hydrophobized poly(dimethylmalic acid) copolymers were 
soluble in water under specific conditions of pH and salt concentration [94]. Solubilization of 
AmB and clofazimine with such PMLA derivatives was also dependent on the pH and salt 
concentration of the aqueous phase. Moreover, the degradation of hydrophobized 
poly(dimethylmalic acid) was not total even after 28 days of incubation [94]. Despite 
encouraging results, improvements are required in order to increase drug loading. 
 This part highlighted also the versatility of synthetic PMLA derivatives which can be 
synthesized in order to form nanoparticles able to entrapped hydrophobic drugs with 
properties (degradation and drug release rates, biocompatibility, etc.) adjusted to the targeted 
application. Moreover, through this rapid overview of works realized with synthetic PMLA 
derivatives, it seems obvious that such degradable and biocompatible polymer family might 
be of interest for the design of site-specific drug delivery using particulate nanovectors. 
 In this context, we have also developed PMLA derivatives (Figure 5) for the design of 
macromolecular materials for biomedical application [18,95] and efficient site specific drug 
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delivery nanoparticles [18,96-99]. All the PMLA derivatives we used were prepared by ring 
opening polymerization of β-substituted β-lactones synthesized from aspartic acid [18,55]. 
 The first step of our project was to determine whether PMLA derivatives could be 
used as water-soluble prodrugs [18,95]. For that, we have synthesized and characterized 
several PMLA derivatives with the goal to use them as: (i) degradable pH-sensitive 
associating networks, (ii) fibroblast growth factor-like terpolymer, (iii) additive for peritoneal 
dialysis bags, or (iv) tissue engineering materials [18,95]. 
To replace the potentially toxic silicone in the formulation of solutions contained into 
peritoneal dialysis bags, we synthesized a PMLA with a molecular weight of 15 000 g/mol 
which shown a high colloid-osmotic pressure. We, therefore, prepared peritoneal dialysis bags 
containing this PMLA and glucose and tested them on rats. Our results evidenced that bags 
containing 2% of the synthesized PMLA and 15 g/L of glucose had the same ultrafiltration 
properties than bags containing 25 g/L of glucose [18]. In view of these results, it might be of 
interest to develop such water soluble polyesters for applications as additive in the preparation 
of peritoneal dialysis bags. 
As described earlier, biocompatible and degradable pH-sensitive hydrogels had 
attracted the attention of several research groups. In this context, we have evaluated the 
potential of a poly(β-malic acid-co-β-malic acid adamantly ester) to form associative networks 
with a β-cyclodextrin (β-CD) copolymer obtained by polycondensation of β-CD with 
epichlorohydrin [18]. Results of physico-chemical characterizations of the mixtures poly(β-
malic acid-co-β-malic acid adamantly ester)/β-CD copolymers demonstrated that a copolymer  
network could be obtained under appropriate conditions and that this  network showed a pH-
sensitivity [18]. Therefore, this pH-sensitive network might be of interest for the design of 
pH-sensitive degradable hydrogel. 
We also developed PMLA derivatives showing wound healing properties. For that 
purpose, we have synthesized a PMLA derivative bearing 60% of carboxylate lateral groups 
(PMLA), 30% of sulfonate lateral groups and 10% of hydrophobic butyl malate units using 
the versatility of both the monomers and polymer’s synthesis [18]. These three specific lateral 
groups have been selected because they were known to interact with natural heparin sulfates 
(HS)-related molecules. Results of in vitro assays showed that the synthesized terpolymer was 
able to protect and stabilize FGFs while results of in vivo experiments evidenced that the 
terpolymer was able to favor muscular regeneration similarly to the most active functionalized 
dextrans mimicking HS functions towards FGFs [18]. These encouraging results evidenced 
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that we were able to prepare macromolecular PMLA derivates with properties adjusted to the 
envisaged biomedical application. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Structures and characteristics of synthetic PMLA derivatives. 
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monomers and polymer’s preparation. The characteristics of the prepared PMLA derivatives 
appeared promising for future biomedical applications. 
Despites the interesting results we obtained with water soluble PMLA derivatives, we 
have next chosen to concentrate our research works on the design of nanoparticulate systems 
based on various hydrophobic or amphiphilic PMLA derivatives for site-specific drug 
delivery [18,96-99].  
The first nanoparticulate systems we developed were based on the hydrophobic PMLA 
derivatives, poly(benzyl malate), poly(isopropyl malate), poly(neohexyl malate), poly(hexyl 
malate) and poly(malic acid-co-hexyl malate) [18,99]. 
Nanoparticles were prepared by the nanoprecipitation method consisting in the 
addition of an acetone solution of the selected polymer into an aqueous solution under 
stirring. After the evaporation of the organic solvent, the nanoparticles solutions were 
analyzed (dynamic light scattering; DLS) and evaluated in various in vitro assays. The 
diameters of the obtained nanoparticles were shown to be dependent on the nature of the 
repeating units and varied from 85 to 160 nm. 
It is worth to note that the zeta potentials were found to be around –30 mV whatever 
the polymer used to prepare the nanoparticles meaning that the terminal carboxylic acid 
functions were located at the surface of the nanoparticles [18,99]. We then investigated the 
degradation behavior of the prepared nanoparticles in various medium at 37°C by size 
exclusion chromatography (molecular weights of the polymers), proton nuclear magnetic 
resonance (NMR) (structure of the degradation products) and DLS (stability of the 
nanoparticles). As expected, results have shown that the degradation rates of the nanoparticles 
constituted by hydrophobic PMLA derivatives were slower than with nanoparticles of more 
hydrophilic PMLA derivatives. Moreover, we have shown that the degradation process 
seemed to be a phenomenon happening randomly in the polymer main chain [18,99]. 
Moreover, we have also demonstrated that the cytotoxicity measured using J774 A1 murine 
macrophage cells was rather mild and dependent upon the rate of degradation of the polymers 
forming the nanoparticles and on the formation of low molecular weight products [99]. 
Finally, we have investigated drug encapsulation capacity of two kinds of nanoparticles, the 
poly(isopropyl malate) and the poly(neohexyl malate) based nanoparticles, with halofantrin, a 
low water soluble drug used in the treatment of malaria [18]. The drug loadings were in the 
range of 5 wt%, the diameters of the resulting charged nanoparticles were correlated to the 
amount of halofantrin added to the nanoprecipitation medium and an inversion of the zeta 
potentials with an increase in the initial amount of halofantrin was observed. We assumed that 
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a part of the drug might be adsorbed at the surface of the nanoparticles. As expected, the 
release of halofantrin was faster in intestinal medium than in PBS and a burst effect was 
observed with 50 % of halofantrin released after 30 min of incubation [18]. All these results 
were very encouraging because they proved that PMLA derivatives might be used as versatile 
polymeric materials for the design of efficient drug delivery systems. 
Therefore, to improve our nanoparticulate systems, we concentrated our efforts on the 
design of fully degradable macromolecular micelles in collaboration with the Professor 
Kataoka’s team [18,96]. To fulfill this objective, we synthesized and characterized three 
amphiphilic block copolymers: poly(malic acid)43-b-poly(butyl malate)7, poly(malic acid)43-b-
poly(butyl malate)10 and poly(malic acid)83-b-poly(butyl malate)14 [96]. 
Because of the presence of carboxylic acid lateral groups on the hydrophilic PMLA 
block, we had to set up a protocol to obtain stable micelles under conditions (pH, salinity, 
etc.) compatible with in vivo applications. After testing several micellization techniques, we 
were able to obtain stable macromolecular micelles by direct dissolution of the amphiphilic 
block copolymers in 10 mM phosphate buffered solution (PBS) at pH7.4 containing 0.15 M 
NaCl. The obtained micelles were characterized by DLS to determine their average diameter 
and their cmc, giving an idea of the micelle stability, was measured by fluorescence using 
pyrene as fluorescence probe [96].The prepared micelles had properties depending on the 
nature and length of each block constituting the amphiphilic block copolymers: the more 
stable micelles, with a diameter of 35 nm and a cmc of 8 mg/L, were obtained with the block 
copolymer having (i) longer hydrophilic and hydrophobic blocks, (ii) a hydrophobic block 
with the higher degree of hydrophobicity, and (iii) a high hydrophilic/hydrophobic ratio [96]. 
Moreover, we have demonstrated that the obtained degradable micelles showed 
properties which were dependent on the pH of the solution. Therefore, such fully degradable 
macromolecular micelles might be of interest as pH-sensitive drug carriers. 
With the aim to design more efficient nanoparticulate systems for site-specific drug 
delivery, we have recently developed targeted stealth nanoparticles based on amphiphilic 
PMLA derivatives constituted by (i) a PEG hydrophilic block conferring stability and stealth 
properties to the resulting nanoparticles, and (ii) a PMLABe hydrophobic block forming the 
inner core of the nanoparticles in which hydrophobic drugs might be encapsulated [97,98]. 
We designed such site-specific nanoparticulate drug delivery systems with the goal to develop 
an efficient drug carrier to treat the Hepatocellular Carcinoma (HCC). Indeed, the HCC 
represents the main primary malignant tumor of the liver representing 80-90% of liver tumor 
and, to date, only very few nanovectors based on polymeric nanoparticles carrying peptides 
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with high tropism for the liver have been developed [100]. Therefore, we synthesized and 
characterized three PMLA derivatives: (i) a hydrophobic PMABe68, (ii) an amphiphilic 
PEG42-b-PMLABe68, and (iii) an amphiphilic block copolymer possessing a targeting moiety, 
the biotin, at the free end chain of the PEG block, Biot-PEG62-b-PMLABe75 [97,98]. We 
selected the biotin as specific molecule for mainly two reasons The biotin is known to be a 
targeting agent of certain cancer cells [101-103] and  it is able to strongly interact with 
streptavidin [104], property we have used to introduce specific short peptides on the outer-
shell of the prepared nanoparticles in order to rapidly screen their specificity towards 
transformed hepatocytes in vitro with the final objective to further selected the most effective 
peptides for direct covalent grafting at the free end chain of the PEG block [98]. We have also 
prepared fluorescent PMLA derivatives by grafting a fluorescein amine molecule at the free 
end chain of the PMLABe block in order to visualize the corresponding nanoparticles into 
cells by flow cytometry of microscopy. Following the synthesis of both monomer and 
polymer, we were able to obtain well-defined PMLA derivatives. 
Starting either from non fluorescent PMLA derivatives or from a mixture of non 
fluorescent and fluorescent block copolymers (50/50 wt%), empty nanoparticles, drug (Dox) 
loaded-nanoparticles or fluorescent probes (1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindodicarbocyanine perchlorate, DiD oil, or 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindotricarbocyanine iodide, DiR) loaded-nanoparticles were prepared by the 
nanoprecipitation technique leading to the obtention of well-defined nanoobjects in a 
reproducible manner [97,98]. 
In vitro cytotoxicity of empty PMLABe68, PEG42-b-PMLABe68 and Biot-PEG62-b-
PMLABe75 based nanoparticles has been evaluated on several cancer cell lines (PC3, NCI, 
Caco, HCT116, MDA, HuH7 and mmt 060562) and human immortalized foreskin fibroblasts. 
These assays revealed that the nanoparticles prepared from the synthesized PMLA derivatives 
might be considered as non toxic in vitro for all the tested cell lines. Indeed, we observed a 
moderated decreased of the cell viability only for high polymer concentrations above 10 µM 
[97]. 
Dox release kinetics from PEG42-b-PMLABe68 and Biot-PEG62-b-PMLABe75 based 
nanoparticles loaded with Dox were followed in water and in culture medium at 37°C. As we 
could expected, we have observed a burst effect within the first hours of incubation with 
about 40% to 50% of Dox released after 10 hours followed by a slow release over the tested  
period (70 hours of incubation) [98]. The treatment of HuH7 cells in vitro with Dox loaded 
into PMLABe68, PEG42-b-PMLABe68 and Biot-PEG62-b-PMLABe75 based nanoparticles 
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induced, as for the free Dox, a dose-dependent cytotoxicity with IC50s similar to the one of 
free Dox. Such results were encouraging in the sense that the efficacy of Dox was not affected 
by the encapsulation process [97]. 
To study the biotin effect on cellular uptake in vitro with mmt 060562cells known to 
overexpress the biotin receptor, we have prepared PEG42-b-PMLABe68 and Biot-PEG62-b-
PMLABe75 based nanoparticles loaded with the fluorescence probe, DiD oil: the red 
fluorescence was only seen in cells that had uptaken DiD oil loaded into Biot-PEG62-b-
PMLABe75 based nanoparticles [97]. 
These results evidenced that the tumor cell targeting with the biotin molecule was 
effective, but we have now to confirm this targeting by performing free biotin competition 
tests. Nevertheless, such results are encouraging and we hypothesized that in vivo treatment of 
biotin overexpressing tumor animal models might give interesting results. 
As mentioned above, besides the use of biotin as a well-known cancer cell’s targeting 
agent, we aimed at developing a versatile procedure to screen more specific targeting agents 
towards transformed hepatocytes in HCC. Our final goal is to select peptides exhibiting a very 
high tropism for the hepatocytes as targeting agents and to graft them at the free chain end of 
the PEG block in order to expose the grafted peptides at the surface of the PMLA derivatives-
based nanoparticles. First, we wished to screen several peptides without engaging more 
organic synthesis in order to select the more active targeting agents. For that purpose, we used 
the non-covalent binding affinity between biotin ad streptavidin. 
In this study, we used fluorescent nanoparticles constituted by a mixture of either 
PEG42-b-PMLABe68 + PEG42-b-PMLABe68-FA (50 wt%) or Biot-PEG62-b-PMLABe75 + 
Biot-PEG62-b-PMLABe75-FA (50 wt%). The presence of the FA molecule had no influence 
on the nanoparticle characteristics. Biotinylated cyclic RGD peptide (Arg-Gly-Asp-DTyr-
Lys-Biot) was first associated to streptavidin followed by the addition of this complex to 
biotinylated fluorescent nanoparticles with defined conditions: 4 µM of block copolymers, 4 
µM of streptavidin and 8 µM of biotinylated RGD peptide [98]. The dilution in PBS or in 
culture medium had no significant influence on biotinylated fluorescent nanoparticles. We 
observed a moderate increase in the diameter and polydispersity index of these nanoparticles 
after the addition of the complex Biot-cRGD/streptavidin in PBS and in culture medium. 
In PBS and culture medium, we also observed a moderate formation of aggregates 
without destabilization of the nanoparticles. We assumed that such limited modifications 
might be considered acceptable for in vitro assays [98]. We therefore performed several in 
vitro assays with the RGD modified nanoparticles in order to evaluate their potential for 
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further in vivo applications [98]. In vitro cell captation by human hepatoma HepaRG cell line 
of RGD-Biot-Streptavidin-Biot-fluorescent nanoparticles was followed using Facs and 
fluorescent microscopy (Figure 6). 
The obtained data demonstrated that the addition of the RGD peptide to the 
biotinylated fluorescent nanoparticles led to a considerable enhancement of cellular uptake of 
the nanoparticles. The results of this analysis highlighted a rapid uptake within the 6 first 
hours which continued slower until 24 hours for RGD modified fluorescent nanoparticles 
while no uptake was observed for biotinylated fluorescent nanoparticles. 
The specificity of the uptake of RGD modified fluorescent nanoparticles by HepaRG 
cells was evaluated by flow cytometry analysis in presence or in absence of an excess of free 
RGD:  results demonstrated that the presence of the RGD peptide on the surface of 
nanoparticles was effectively responsible of the increased uptake by HepaRG cells of RGD 
modified fluorescent nanoparticles. 
Figure 6. Fluorescence microscopy and flow cytometry analysis of HepaRG cells incubated 
with (a). Biot-PEG62-b-PMLABe75 nanoparticles (NPs), (b). Biot-PEG62-b-PMLABe75 + Biot-
PEG62-b-PMLABe75-FA NPs, and (c). RGD-biot/Streptavidin/Biot-PEG62-b-PMLABe75 + 
Biot-PEG62-b-PMLABe75-FA NPs. 
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The uptake of biotinylated fluorescent nanoparticles and RGD modified fluorescent 
nanoparticles by three different cell lines (HepaRG, HT29 and HeLa cancer cells) was then 
studied by flow cytometry (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Fluorescence microscopy (upper panel) and flow cytometry analysis (charts on the 
lower panel) of HepaRG, HT29 and HeLa cells incubated with biotinylated fluorescent 
nanoparticles and RGD modified fluorescent nanoparticles for 24 hours. 
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slightly higher than the one of positive HepaRG cells. However, the degree of uptake in HeLa 
cells was much lower than in HepaRG cells. Such results indicated that the RGD peptide had 
a real tropism for liver cells.  
In our study, we demonstrated that the molecular scaffold Pept-Biot-Streptavidin-Biot-
NPs might be used to screen for other short peptides targeting hepatocytes and HCC. We have 
already selected short peptides (<20 amino acids), which might present an interest for our 
studies. Our goal will be to select two or three of the more efficient peptides to graft them at 
the free chain end of PEG block to avoid the use of immunogenic streptavidin for further in 
vivo biodistribution assays. 
In the meantime, we have already realized a preliminary in vivo study in nude BALB/c 
mice by intravenous injection of Biot-PEG62-b-PMLABe75nanoparticles modified or not with 
RGD peptide and loaded with the DiR fluorescent probe. The preliminary results indicated 
that these nanoparticles were well tolerated with no signs of toxicity. Moreover, we were able 
to detect fluorescence in the living animal thus demonstrating that our experimental 
conditions were compatible with this kind of study. In addition, the first analyses seemed to 
highlight a more important abdominal accumulation of the RGD modified nanoparticles 
loaded with DiR in comparison to the biotinylated nanoparticles encapsulated DiR. We have 
now to confirm the exact localization of the RGD modified nanoparticles loaded with DiR. 
Moreover, we will move to the injection of directly modified nanoparticles by the selected 
peptides without the use of immunogenic streptavidine molecule to check their in vivo 
biocompatibility, biodistribution and efficiency against HCC. 
 
Conclusion 
Through this overview, we highlighted that both natural and synthetic PMLA derivatives 
might be considered as promising biocompatible and degradable polymeric materials for 
applications in the field of drug delivery systems. While a lot of works have been realized 
mainly by Ljubimova’s groups on natural PMLA, only limited researches have been 
conducted on synthetic PMLA derivatives despites the interesting results already obtained. 
Until now, PMLA derivatives (either natural or synthetic ones) are still at the step of 
preclinical trials  even if some in vivo assays have been conducted. At  the moment, to the 
best of our knowedge, no phase III  or clinical evaluations have been published despites 
encouraging results obtained on such materials. Therefore, we will continue our efforts to 
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design efficient biocompatible nanoparticulate drug carriers based on synthetic PMLA 
derivatives for HCC treatments. 
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